Therefore, antibodies targeting the IL-6 receptor (tocilizumab and sarilumab), IL-6 (siltuximab), and other receptor antagonists (α1-adrenergic receptor antagonist, prazosin) for mitigating cytokine storm are promising therapeutic strategies for the treatment of cancer patients with COVID-1935. This evidence concerns the gene IL6 and cancer.